NAYA Therapeutics is developing NK cell engagers (NY-303 GPC3×NKp46; NY-338 CD38×NKp46) and an At-211 radiopharmaceutical (NY-700) for HCC. Clinical plan targets H2 2025 FIH for NY-303. Risks include lack of human proof for NKp46 engagers and operational constraints for At-211 logistics. Market: HCC non-responders; differentiation via NK safety profile and short-range alpha emission.
